These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 15975897

  • 1. Releasing the pressure.
    Davenport RJ.
    Sci Aging Knowledge Environ; 2005 Jun 22; 2005(25):nf47. PubMed ID: 15975897
    [No Abstract] [Full Text] [Related]

  • 2. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF, Lohray BB.
    J Clin Pharmacol; 2008 Aug 22; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract] [Full Text] [Related]

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 4. Fluid retention with thiazolidinediones: does the mechanism influence the outcome?
    Lindenfeld J, Masoudi FA.
    J Am Coll Cardiol; 2007 Apr 24; 49(16):1705-7. PubMed ID: 17448372
    [No Abstract] [Full Text] [Related]

  • 5. Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?
    Baskin S, Neher JO, Dodson S, Hoffman R.
    J Fam Pract; 2005 Aug 24; 54(8):723-4. PubMed ID: 16061064
    [No Abstract] [Full Text] [Related]

  • 6. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A, Strojek K.
    Kardiol Pol; 2006 Mar 24; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract] [Full Text] [Related]

  • 7. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime.
    Leier CV, Haas GJ.
    J Am Coll Cardiol; 2007 Jul 03; 50(1):37-9. PubMed ID: 17601543
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. TZDs and diabetes: testing the waters.
    Semenkovich CF.
    Nat Med; 2005 Aug 03; 11(8):822-4. PubMed ID: 16079871
    [No Abstract] [Full Text] [Related]

  • 10. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 03; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [PPARgamma].
    Itoh H.
    Nihon Rinsho; 2006 Jul 03; 64 Suppl 5():182-91. PubMed ID: 16897862
    [No Abstract] [Full Text] [Related]

  • 13. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.
    Nat Med; 2005 Aug 03; 11(8):861-6. PubMed ID: 16007095
    [Abstract] [Full Text] [Related]

  • 14. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
    Zieleniak A, Wójcik M, Woźniak LA.
    Arch Immunol Ther Exp (Warsz); 2008 Aug 03; 56(5):331-45. PubMed ID: 18836859
    [Abstract] [Full Text] [Related]

  • 15. Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.
    Yoshioka K, Wakino S, Homma K, Kanda T, Tatematsu S, Hasegawa K, Sugano N, Ito O, Omata K, Saruta T, Hayashi K.
    Obesity (Silver Spring); 2008 May 03; 16(5):965-71. PubMed ID: 18277387
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A second chance for a PPARγ targeted therapy?
    Norris AW, Sigmund CD.
    Circ Res; 2012 Jan 06; 110(1):8-11. PubMed ID: 22223206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.